NDA 050783 · Galderma Labs Lp
Periostat
Doxycycline Hyclate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Feb 2, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
424
81 Phase 3, 42 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PERIOSTAT · DOXYCYCLINE HYCLATE EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxycycline Hyclate" as an intervention, any sponsor and status, largest first.
- Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsPivotal-lookingEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT04297592 · 4,618 participants (planned) · Start Jun 11, 2020 · Primary completion Jan 2027
Drug: Cephalexin; Doxycycline and 1 more · For: Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization and 6 more
Sites: Iowa City, Iowa; Rochester, Minnesota
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSMPivotal-lookingActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT06468462 · 2,900 participants (planned) · Start Oct 29, 2025 · Primary completion Oct 31, 2028
Drug: WHO-recommended periodic presumptive treatment; Doxycycline post-exposure prophylaxis · For: Gonorrhea Male; Chlamydia (Male); Syphilis Male
Sites: Kisumu, Kenya; Mombasa, Kenya; Nairobi, Kenya
- To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of PregnancyPivotal-lookingCompleted
The University of Hong KongAcademic, hospital or other
NCT01842100 · 2,193 participants · Start Sep 1999 · Primary completion Feb 2006
Drug: Universal antibiotic prophylaxis · For: Induced Abortion; Postaboral Pelvic Inflammatory Disease; Sexually Transmitted Infections
Sites: Hong Kong, China
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm BirthPivotal-lookingNot yet recruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT06349122 · 1,794 participants (planned) · Start Oct 2026 · Primary completion Jun 2029
Drug: Azithromycin; Ceftriaxone and 3 more · For: Bacterial Vaginosis; Vaginal Dysbiosis; Premature Delivery
- Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic FilariasisCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00340691 · 1,500 participants · Start Dec 6, 2004 · Primary completion Oct 4, 2007
Drug: Doxycycline · For: Mansonella Perstans Infection; Mp Microfilaremia
Sites: Bethesda, Maryland
Galderma R&DIndustry
NCT00892281 · 1,421 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy; doxycycline (Oracea®) 40 mg modified release as add-on therapy · For: Rosacea
Sites: Lexington, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.
Stewart J, Oware K, Donnell D, et al. · N Engl J Med 2023 · Comparative Study, Randomized Controlled Trial
- Comparative evaluation of demineralized freeze-dried bone allograft with and without doxycycline hyclate loaded proniosomal gel in the treatment of class II furcation defects: a randomized controlled trial.
Biradar V, Mody D, Kolte AP, et al. · Clin Oral Investig 2025 · Randomized Controlled Trial, Comparative Study
- Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis.
Pagès F, Boutin JP, Meynard JB, et al. · Trop Med Int Health 2002 · Clinical Trial, Randomized Controlled Trial
- Local prolonged release of antibiotic for prevention of sternal wound infections postcardiac surgery-A novel technology.
Kachel E, Moshkovitz Y, Sternik L, et al. · J Card Surg 2020 · Multicenter Study, Randomized Controlled Trial
- Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.
Salminen A, Pussinen PJ, Payne JB, et al. · Inflamm Res 2013 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Systematic review and meta-analysis on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts.
Smiley CJ, Tracy SL, Abt E, et al. · J Am Dent Assoc 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.